Point72 Asia Singapore Pte. Ltd. Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 46.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,593 shares of the specialty pharmaceutical company's stock after buying an additional 4,627 shares during the period. Point72 Asia Singapore Pte. Ltd.'s holdings in Jazz Pharmaceuticals were worth $1,626,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Versant Capital Management Inc increased its stake in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock worth $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after buying an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $33,000. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Up 0.8 %

JAZZ traded up $0.94 on Monday, hitting $122.53. The company had a trading volume of 176,007 shares, compared to its average volume of 673,244. The company has a market cap of $7.41 billion, a PE ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The business's fifty day simple moving average is $114.87 and its 200 day simple moving average is $111.13. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,110 shares of company stock worth $720,160. Company insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on JAZZ. TD Cowen lowered their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a report on Monday, August 19th. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research note on Monday, November 18th. Finally, Royal Bank of Canada increased their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $175.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.